Related Experiment Video

Updated: Nov 12, 2025

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells

Published on: September 1, 2010

Frondoside A Inhibits an MYC-Driven Medulloblastoma Model Derived from Human-Induced Pluripotent Stem Cells

Yingchao Xue¹, Yi Fu¹, Fenghong Zhao¹

¹Hugo W. Moser Research Institute at Kennedy Krieger, Baltimore, Maryland.

Molecular Cancer Therapeutics

|March 16, 2021

Abstract:

Medulloblastoma (MB) is the most common malignant pediatric brain tumor. MYC-driven MBs, commonly found in the group 3 MB, are aggressive and metastatic with the worst prognosis. Modeling MYC-driven MB is the foundation of therapeutic development. Here, we applied a synthetic mRNA-driven strategy to generate neuronal precursors from human-induced pluripotent stem cells (iPSCs). These neuronal precursors were transformed by the MYC oncogene combined with p53 loss of function to establish an MYC-driven MB model recapitulating the histologic and transcriptomic hallmarks of group 3 MB. We further show that the marine compound Frondoside A (FA) effectively inhibits this MYC-driven MB model without affecting isogenic neuronal precursors with undetectable MYC expression. Consistent results from a panel of MB models support that MYC levels are positively correlated with FA's antitumor potency. Next, we show that FA suppresses MYC expression and its downstream gene targets in MB cells, suggesting a potential mechanism underlying FA's inhibitory effects on MYC-driven cancers. In orthotopic xenografts of MYC-driven MB, intratumoral FA administration potently induces cytotoxicity in tumor xenografts, significantly extends the survival of tumor-bearing animals, and enhances the recruitment of microglia/macrophages and cytotoxic T lymphocytes to tumors. Moreover, we show that MYC levels also predict FA potency in glioblastoma and non-small cell lung cancer cells. Taken together, this study provides an efficient human iPSC-based strategy for personalizable cancer modeling, widely applicable to mechanistic studies (e.g., genetic predisposition to cancer) and drug discovery. Our preclinical results justify the clinical translation of FA in treating MYC-driven MB and other human cancers.

Insights

A new model for aggressive pediatric brain tumors (medulloblastoma) was created using human stem cells. The marine compound Frondoside A effectively targets these MYC-driven tumors, showing promise for new cancer therapies.

Area of Science:

Neuro-oncology
Cancer Biology
Stem Cell Research

Background:

Medulloblastoma (MB) is the most common malignant pediatric brain tumor, with MYC-driven group 3 MB exhibiting aggressive behavior and poor prognosis.
Developing accurate models of MYC-driven MB is crucial for advancing therapeutic strategies.
Current therapeutic approaches for this aggressive cancer remain limited.

Purpose of the Study:

To establish a novel human induced pluripotent stem cell (iPSC)-based model of MYC-driven medulloblastoma.
To investigate the therapeutic potential of the marine compound Frondoside A (FA) against MYC-driven MB.
To explore the correlation between MYC expression levels and FA's efficacy in various cancer models.

Main Methods:

Generation of neuronal precursors from human iPSCs using synthetic mRNA technology.
Transformation of neuronal precursors with the MYC oncogene and p53 loss-of-function to create an MB model.
Treatment of the MB model and other cancer cell lines with Frondoside A (FA).
Assessment of FA's effects in orthotopic xenograft models, including tumor cytotoxicity, animal survival, and immune cell infiltration.

Main Results:

A novel MYC-driven medulloblastoma model was successfully established, recapitulating key features of group 3 MB.
Frondoside A demonstrated potent inhibition of MYC-driven MB models, with efficacy correlated to MYC expression levels.
FA suppressed MYC expression and downstream targets, induced tumor cell death, improved survival in vivo, and enhanced anti-tumor immune responses.
FA's efficacy was also observed in glioblastoma and non-small cell lung cancer models, suggesting broader applicability.

Conclusions:

The iPSC-based model provides an efficient platform for personalized cancer modeling and drug discovery.
Frondoside A exhibits significant preclinical efficacy against MYC-driven medulloblastoma and other cancers.
These findings support the clinical translation of Frondoside A for treating MYC-driven malignancies.

Read full analysis

More Related Videos

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Intracranial Orthotopic Allografting of Medulloblastoma Cells in Immunocompromised Mice

Published on: October 3, 2010

A Novel Stromal Fibroblast-Modulated 3D Tumor Spheroid Model for Studying Tumor-Stroma Interaction and Drug Discovery

A Novel Stromal Fibroblast-Modulated 3D Tumor Spheroid Model for Studying Tumor-Stroma Interaction and Drug Discovery

Published on: February 28, 2020

Related Concept Videos

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...

Induced Pluripotent Stem Cells

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different types of cells. Ordinarily, cells that have differentiated into a specific cell type are post-mitotic—that is, they no longer divide. However, scientists have found a way to reprogram these mature cells so that they “de-differentiate” and return to an unspecialized, proliferative state. These cells are also pluripotent like embryonic stem cells—able to produce all cell types—and are therefore...

EPS and iPS Cells in Disease Research

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...

Articles linked to this work by shared authors, journal, and citation graph.

Local Sustained Delivery of Temozolomide via an Injectable Poly(Anhydride-Ester) Depot for Glioblastoma Therapy.

Pharmaceutics·2026

ALT phenotype assessment in IDH-mutant astrocytoma supports biologic consequence of ATRX missense mutations.

Brain pathology (Zurich, Switzerland)·2026

The CoREST complex inhibitor, corin, decreases tumor growth, increases cellular differentiation and extends lifespan in ATRT xenograft models.

Neuro-oncology·2026

MYC Is Functionally Required in Both Normal and Neoplastic Meibomian Glands.

The American journal of pathology·2026

Case Report: Bilateral optic nerve head masses and retinopathy in a patient with B-cell acute lymphoblastic leukemia receiving CAR T-cell therapy masquerading as fungal endophthalmitis.

Frontiers in immunology·2026

The dual role of Schlafen11 in brain tumors: Jekyll and Hyde.

Expert review of anticancer therapy·2026

See all related articles